General Session VII - Superficial Venous Disease and Vascular Malformations
Quickshot: VEIN STEP Mexico: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease
Tuesday, March 5, 2024
5:41 PM – 5:47 PM EST
Location: Tampa Bay Ballroom Salons 1-4
Objective: VEIN STEP Global was conducted to collect international data on the management of chronic venous disease (CVD) and assess the effectiveness of conservative treatments for the relief of CVD symptoms. We aim to present the data gathered from the population in Mexico.
Methods: This international, observational, prospective study recruited adult outpatients consulting for symptomatic CVD. We are presenting data evaluated from a population recruited in Mexico. Patients underwent a clinical evaluation using the Clinical Etiology Anatomy Pathophysiology (CEAP) classification. Patients received initial treatment with venoactive drugs (VAD), compression, lifestyle change, etc. according to each physician’s judgment. Candidates for immediate interventional treatment were excluded. Up to 8 weeks outcomes were evaluated using a 10cm visual analog score (VAS) and QoL using the CIVIQ-14 questionnaire and VCSS. Clinical changes over time were analyzed using a Wilcoxon test. And between-group analysis using a ranked ANCOVA with baseline value as covariates adjusted on main baseline characteristics and relevant concomitant treatments.
Results: The analysis set comprised 803 subjects (78% female) with a mean age of 52±14.2 years and BMI of 28.4±4.9 kg/m2 (Table 1). The most common CEAP classifications were C1 (30.4%), C2 (30.6%), and C3 (30.7%). Conservative therapy could be prescribed according to clinical practice, as monotherapy or in combination, and consisted of oral venoactive drugs (VADs, 95.8% of subjects) including micronized purified flavonoid fraction (MPFF 75.5%) and diosmin (18.8%); compression (52.0%), and topicals (31.5%). Conservative therapy was associated with a significant decrease over time in mean: VAS 5.7(±2.73) vs 3.2(±2), VCSS 6.3 (±4.1) vs 4.4 (±2.9), and CIVIQ-14 42.7 (± 21.8) vs 20.9 (± 16.3) (P < 0.001).
Conclusions: VEIN STEP Mexico provides large-scale data with follow-up from real-life settings including both patient-reported outcomes and physicians’ assessments. The results show that conservative treatment, primarily venoactive medications, is associated with significant improvements in symptoms, signs, and quality of life in patients with CVD.
